Lung Cancer Considered

Radon exposure is a known risk factor for lung cancer yet it does not garner as much attention as other risk factors. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses radon, its impact on lung cancer diagnosis, new research covering radon and strategies to improve our patients and the general population's exposure to this radioactive gas. Her guest is Dr. Hina Khan, tho...

Radiologists play central roles in the detection of lung cancer, in assessing response to therapy and relapse of disease and increasingly, interventional radiologists are involved with tissue sampling and lung cancer treatment. In this episode of Lung Cancer Considered, host Dr. Stephen Liu interviews two noted radiologists--Dr. Carole Ridge and Dr. Florian Fintelmann. Dr. Ridge is a consultant ra...

This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medi...

In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in Israel, spoken in Hebrew. Host Dr. Alona Zer, Head of the Department of Medical Oncology at the Rambam Health Care Campus, Haifa, Israel welcomes guests Dr. Jair Bar, Deputy Director, Institute of Oncology at Chaim Sheba Medical Center and Associate Professor of Oncology, School of M...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu and invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the ESMO Asia meeting held in Singapore. Guests include Dr. James Yang, director and Professor of the Graduate Institute of Oncology at the National Taiwan University and the director of the Department of Oncology at the National Taiwan Un...

In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in the Middle East (North Africa), spoken in Arabic. Host Dr. Nagla Karim, MD, PHD, Director of the Phase I Program at the Inova Schar Cancer Institute welcomes guests Dr. Abdelrahman Mohamed, MD, Head of Thoracic Surgery, NCI at Cairo University and Dr. Houssein Abdul Sater, MD, Physic...

This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Dir...

This episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022. His guests are Dr. Jordi Remon, a thoracic medical oncologist who had...

Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).

There has been a steady stream of research presented that ties air pollution to an increased risk for lung cancer. To discuss this trend, Lung Cancer Considered host Dr. Narjust Florez interviews Dr. Roselle De Guzman, who is a medical oncologist and professor at the Manila Central University in the Philippines and the Chair of ASCO Asia Pacific Regional Council. Joining her is Dr. Christine D. Be...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu, Director of Thoracic Oncology at Georgetown University, leads a discussion about the management of stage III NSCLC. Joining him are pulmonologist Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and thoracic surgeon Dr. Paula Antonia Ugalde Fi...

At the time it was published in the New England Journal of Medicine in 2002, ECOG 1594 was the first study to compare whether any of the three chemotherapy regimens used at the time was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez interview the ECOG 1594 clinical tr...

Lung cancer research is often centered at large, urban academic medical centers. But what research and treatment options are available for those patients with lung cancer who live in rural areas? In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses the state of rural lung cancer care and research with Dr. Debora Bruno, a thoracic medical oncologist at Case Western in Clevel...

In this special edition of Lung Cancer Considered, three esteemed oncologists and lung cancer experts explore the issues facing the medical profession in China. Host Dr. Chunxia Su, Professor of Oncology at Tongji University and Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital, welcomes guests Prof. Shun Lu, Director of the Chinese Lung Cancer Association, Board Member of the Chi...

In keeping with its mission to cover lung cancer from a global perspective, this episode of Lung Cancer Considered focuses on lung cancer in Japan. Host Dr. Misako Nagasaka, a Thoracic Medical Oncologist from the University of California Irvine leads a Japanese-language discussion about lung cancer in Japan with respected oncologists Dr. Tetsuya Mitsudomi and Dr. Takashi Seto. Dr. Seto is a Thorac...

Over the past few years, the use of liquid biopsy has improved the ability to detect biomarkers for non-small cell lung cancer. In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the current state of liquid biopsies with Dr. David Gandara, Professor of Medicine and Director of Thoracic Oncology at the University of California, Davis; Dr. Charu Aggarwal, the Lesly...

In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks about the critical role interventional pulmonologists play on the cancer care team. Joining the discussion are Dr. Daniel Sterman, the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine at the New York University Grossman School of Medicine and Dr. Rebecca Krochmal, Assistant Professor of Medicine in...

Did you miss ESMO this year? Listen to Lung Cancer Considered host and thoracic oncologist Dr. Narjust Florez discuss the key highlights involving science and notable abstracts at the meeting with Dr. Joshua Reuss, Thoracic Medical Oncologist and Assistant Professor of Medicine at Georgetown and Dr. Giannis Mountzios, Director of the Oncology Department and Clinical Trials Unit at Henry Dunant Hos...

The role of the pathologist in lung cancer treatment has dramatically evolved as our understanding of lung cancer biology has advanced. Lung Cancer Considered host Dr. Stephen Liu discusses that evolution with renowned lung cancer pathologists Dr. Dara Aisner from the University of Colorado and Dr. Ignacio Wistuba from MD Anderson Cancer Center. Dr. Wistuba is a Professor in the Department of Thor...

Lung Cancer Considered Host Dr. Stephen Liu leads a recap of the recently completed IASLC 2022 North America Conference on Lung Cancer featuring guests Dr. Jessica Donington, Professor and Chief Thoracic Surgery University of Chicago; Dr. Jyoti Patel, Thoracic Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University and Dr. Shruti Patel, Oncology Fellow at Stanford Sch...

Career transitions are normal in academic oncology, oncology practice, and industry and today's oncologists go through a number of 'job' interviews during their post-graduate life and early career. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses how to find or transition to that new job in thoracic oncology. Joining the discussion are three lung cancer researchers: Dr....

Treatment for malignant pleural mesothelioma has undergone dramatic shifts in the past few years. To discuss these changes and the research behind them, Lung Cancer Considered Host Dr. Stephen Liu welcomes Dr. Sanjay Popat and Dr. Melina Marmarelis. Dr. Popat is a Consultant Thoracic Medical Oncologist at The Royal Marsden and Professor of Thoracic Oncology at the Institute of Cancer Research, in...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the management of metastatic, PDL1 negative NSCLC. He is joined by Dr. Hossein Borghaei and Dr. Reyes Bernabe Caro. Dr. Borghaei is a professor and Chief of Thoracic Oncology at Fox Chase Cancer Center in Philadelphia. He was the lead author for CheckMate 057, was involved in many of the landmark immunotherapy tr...

On the heels of accelerated approval by the US FDA, Dr. Stephen Liu discusses trastuzumab-deruxtecan (T-DXd) with medical oncologists and clinical investigators, Dr. Lyudmila Bazhenova, from the University of California, San Diego, and Dr. Julian Mazieres, from Toulouse University Hospital. T-DXd is an antibody-drug conjugate now approved for the treatment of HER2-mutant NSCLC, and in this episode...

It’s a wrap! Catch up on key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy.